Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.55 |
| ▸ | NPY4R | P50391 | 10/20 | 0.47 |
| ▸ | NPY1R | P25929 | 7/20 | 0.47 |
| ▸ | NPY2R | P49146 | 6/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31024641 | 1.00 | SIRT6 (0.57) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL15987249 | 0.93 | SIRT5 (0.57) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL16045801 | 0.93 | SIRT5 (0.57) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL29397145 | 0.91 | SIRT6 (0.56) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL29396582 | 0.91 | SIRT6 (0.56) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL29396719 | 0.91 | SIRT6 (0.56) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL23335231 | 0.89 | SIRT6 (0.47) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL15185942 | 0.89 | NPY4R (0.56) | SIRT6SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL10169080 | 0.88 | NPY4R (0.54) | SIRT6SIRT1NPY4RNPY1RNPY2R | |
| SCHEMBL24900018 | 0.88 | SIRT5 (0.49) | SIRT6SIRT1SIRT5NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367852-B1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | SEDERMA SA (FR) | 2023-08-30 | — | — | EP | disclosed |
| EP-3744729-B1 | PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES | SEDERMA SA (FR) | 2023-03-01 | — | — | EP | disclosed |
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | ANTEIS SA (CH) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | CUTA, PLOD3, MMP13 | SIRT6 644/4885SIRT1 273/4885SIRT5 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.